Necessity of Aspiration in the Ventrogluteal Site
Investigation of the Necessity of Aspiration During The Intramuscular Injection Administered in the Ventrogluteal Site and Its Effect on Pain
1 other identifier
interventional
834
1 country
1
Brief Summary
H1: Aspiration is not necessary for IM injections applied from the ventrogluteal region. H2: Aspiration procedure increases pain in IM injections applied from ventrogluteal region. H3: The duration of the aspiration procedure on IM injections applied from the ventrogluteal region is effective on pain.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 14, 2019
CompletedFirst Submitted
Initial submission to the registry
June 4, 2020
CompletedFirst Posted
Study publicly available on registry
June 9, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 10, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
June 20, 2020
CompletedJune 11, 2020
June 1, 2020
1.4 years
June 4, 2020
June 9, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Individual Introductory Information Form
The content of the study was explained to the patients coming to the emergency room. Written informed consents were obtained in line with the "Individual Introductory Information Form" of the patients. Individual Introductory Information Form: This form includes questions such as the patient's application group, diagnosis, age, gender, height, weight, and blood intake during aspiration in intramuscular injection. It is completed within the first 10-15 minutes of contact with the patient.
15 minutes
Visual Analog Scale (VAS)
Intramuscular injection was performed in accordance with the application group assigned to the patients who filled the Individual Introductory Information Form. The patients were not told which group they belonged to. A nurse who except the researcher who performed the application evaluated pain levels that patients feel during injection immediately after the intramuscular injection application, with a Visual Analog Scale. The minimum score that can be obtained from this scale is 0 and the maximum score is 10. A higher score indicates that the pain is more severe. This scale was applied in minutes 1-5 after intramuscular injection.
5 minutes
Study Arms (3)
Experimental Group A
EXPERIMENTALExperimental Group A who were administered intramuscular injection during which aspiration lasted for 5-10 seconds.
Control Group
NO INTERVENTIONControl Group who were administered intramuscular injection during which aspiration lasted for 1-2 seconds.
Experimental Group B
EXPERIMENTALExperimental Group B who were not administered aspiration during IM injection.
Interventions
The patients who met the inclusion criteria and agreed to participate in the study were assigned to the Experimental Group A who were administered IM injection during which aspiration lasted for 5-10 seconds, to the Control Group who were administered IM injection during which aspiration lasted for 1-2 seconds, and to the Experimental Group B who were not administered IM injection according to the stratified block randomization list. The same "Intramuscular Injection Application Protocol" was applied while all the injections were administered.
Eligibility Criteria
You may qualify if:
- Patient who came to the Emergency Service Care Unit for "Diclofenac Sodium" injection
- Have no vision and hearing problems,
- Who have no disease that may affect their perception of pain
- Who can evaluate the "Visual Analog Scale" correctly, scoring 5 points or less from the VAS,
- Body Mass Index is between 18.5-24.9 kg / m2,
- Who do not have any discomfort in the extremities that will prevent them from taking the desired position,
- No complications due to intramuscular injections such as abscess, infection, tissue necrosis and hematoma in the ventrogluteal region
- No nodules or masses in the area
You may not qualify if:
- Patients who refuse the injection are excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ege Universitylead
Study Sites (1)
Ege University Hospital
Izmir, Turkey (Türkiye)
Related Publications (2)
Beyea SC, Nicoll LH. Administration of medications via the intramuscular route: an integrative review of the literature and research-based protocol for the procedure. Appl Nurs Res. 1995 Feb;8(1):23-33. doi: 10.1016/s0897-1897(95)80279-7.
PMID: 7695353BACKGROUNDBaran L, Gunes U, Donmez H. Investigation of the Necessity of Aspiration During the Intramuscular Injection Administered in the Ventrogluteal Site and Its Effect on Pain: A Randomized Controlled Trial. Clin Nurs Res. 2023 May;32(4):821-829. doi: 10.1177/10547738221136470. Epub 2022 Dec 20.
PMID: 36540016DERIVED
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr.
Study Record Dates
First Submitted
June 4, 2020
First Posted
June 9, 2020
Study Start
January 14, 2019
Primary Completion
June 10, 2020
Study Completion
June 20, 2020
Last Updated
June 11, 2020
Record last verified: 2020-06
Data Sharing
- IPD Sharing
- Will not share